November 2025 in “Drug Testing and Analysis” This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.
18 citations
,
July 2009 in “Drug Metabolism and Disposition” This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.
2 citations
,
December 2013 in “Xenobiotica” This study found that the metabolic profile of finasteride in pigs closely matches that of humans, supporting the use of pigs for studying human drug metabolism.
2 citations
,
January 1997 in “Principles of Medical Biology” This article reviews the role of enzymatic processes in drug and toxin metabolism, emphasizing their impact on solubility and elimination, without presenting new clinical findings.
January 2026 in “RSC Advances” This study used a zebrafish model and advanced mass spectrometry to identify 11 metabolites of epristeride, revealing significant effects on purine metabolism and aromatic amino acid biosynthesis, which may aid in developing anti-doping detection methods.